Condition: Prostate Cancer · Sponsor: AstraZeneca
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Orlando, Florida, United States | Recruiting |
| Research Site | Tampa, Florida, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Withdrawn |
| Research Site | Grand Rapids, Michigan, United States | Recruiting |
| Research Site | Commack, New York, United States | Recruiting |
| Research Site | Providence, Rhode Island, United States | Recruiting |
| Research Site | Ghent, Belgium | Not Yet Recruiting |
| Research Site | Toronto, Ontario, Canada | Not Yet Recruiting |
| Research Site | Québec, Canada | Not Yet Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Chengdu, China | Suspended |
| Research Site | Guangzhou, China | Suspended |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07192614